Short treatment with sofosbuvir and ledipasvir over only 6 weeks is sufficient to cure acute hepatitis C (HCV)
A pilot study presented today found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a ‘short-duration’ of six weeks had undetectable HCV after a 12 week follow-up. The investigator-initiated study, presented at The International Liver CongressTM in Barcelona, Spain, demonstrated that the combination of sofosbuvir and ledipasvir for only six weeks is sufficient to treat patients with acute HCV.
Those infected with HCV usually develop acute Hepatitis C, which spontaneously clears in 10 to 50% of infected persons. Early diagnosis of HCV infection is rare and the disease may go unnoticed until patients have already developed serious liver damage.1 Sofosbuvir and ledipasvir is one possible regimen for treatment of patients with chronic HCV. Sustained virologic response (SVR) is greater than 95% with a 12-week course of this treatment.2
“Given the high cost of sofosbuvir and ledipasvir, and the associated side effects that occur during treatment, we set out to assess whether shortened treatment duration could be an effective option for acute Hepatitis C patients,” said Katja Deterding from Hannover Medical School, Germany and study author. “Our research demonstrates that not only is the combination of sofosbuvir and ledipasvir safe, well tolerated and effective in acute HCV genotype 1 patients who have severe liver disease with very high liver enzymes, but a shorter treatment duration does not appear to hinder efficacy,” confirmed Professor Heiner Wedemeyer, the senior author of this study.
The German pilot study, performed by the German HepNet Study-House included 20 patients. Risk factors of HCV infection among the study members included; sexual transmission (n=11), medical procedures/needle stick injury (n=5), drug use (n=1), and nail treatment complications (n=1). The causes were unspecified for the remaining two patients.
All 20 patients completed six weeks of sofosbuvir and ledipasvir without ribavirin. At the 12 week follow up, all 20 patients had undetectable HCV and achieved SVR (100%). Fatigue was the most frequent side effect reported by study members (30%).
“These exciting findings open up short and cost-effective treatment options that could prevent the spread of HCV in high risk populations,” said Professor Frank Tacke, EASL Governing Board member. “We look forward to seeing this pilot study extended so the findings can be validated and then hopefully used as a tool to change clinical practice for the better.”
The Latest on: Hepatitis C
via Google News
The Latest on: Hepatitis C
- Outlook on the Worldwide Hepatitis C Drugs Industry to 2025 - Featuring Abbvie, Gilead Sciences, Merck & Co & Bristol-Myers Squibb Among Otherson May 12, 2020 at 3:33 am
The "Hepatitis C Drugs Market Global Forecast By Drugs, Distribution Channels, Regions, Company Analysis" report has ...
- Hepatitis alert: Rats are infecting humans with deadly virus - 11 confirmed cases in Asiaon May 12, 2020 at 1:17 am
HEPATITIS E has started jumping from rats to humans in Hong Kong, causing patients to be hospitalised with a number of symptoms. After 11 cases have been confirmed in Asia, scientists are concerned ...
- Drunk woman with HIV and Hepatitis C took a soiled sanitary pad from her underwear and threw it at a copon May 11, 2020 at 11:28 am
Drunk woman with HIV and Hepatitis C took a soiled sanitary pad from her underwear and threw it at a cop A drunk woman diagnosed with HIV and Hepatitis C who shoved a used sanitary pad in a police ...
- COVID-19 Impact on Hepatitis C Drug Market Size 2020 Top Manufactures Analysis by AbbVie, Gilead, Kenilworthon May 11, 2020 at 3:07 am
Hepatitis C Drug Market"report givesAnalysis of incomes, limits, and benefitsof Key Manufacturers in Healthcare ...
- Combination of HIV, hepatitis C, MS drugs might resolve COVID-19 infectionon May 8, 2020 at 3:49 pm
Combination therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin appears to improve symptoms and shorten hospital stays for people with mild to moderate COVID-19.
- Hepatitis C virus (HCV) Testing Market- Growth Insight, Future Scope, Market Status, Rising Demand, Industry Trend, 2027on May 8, 2020 at 5:12 am
Recent report published by research nester titled "Global Hepatitis C Virus (HCV) Testing Market: Global Demand ...
- Recommendations to Screen All Pregnant Women for Hepatitis C Draw Pushbackon May 5, 2020 at 11:00 am
New guidelines say pregnant women should get tested for the hepatitis C virus, recommendations that some doctors say are unnecessary.
- CDC Calls for Universal Hepatitis C Screening to Halt Advanced Liver Disease & Liver Cancer: Echosens Emphasizes Vigilance, Supports Hepatitis Awareness Monthon May 5, 2020 at 5:45 am
CDC Calls for Universal HCV Screening to Halt Advanced Liver Disease & Liver Cancer: Echosens Emphasizes Vigilance, Supports Hepatitis Awareness Month ...
- Hepatitis C Drugs May Help Fight COVID-19, Suggests Studyon May 5, 2020 at 2:29 am
Several drugs approved for the treatment of hepatitis C viral infection have been identified as potential candidates against COVID-19 caused by the SARS-CoV-2 coronavirus, according to a study based ...
- Hepatitis C drugs may help fight COVID-19, supercomputer simulations suggeston May 5, 2020 at 1:02 am
Using the powerful MOGON II supercomputer operated by JGU and the Helmholtz Institute Mainz, the researchers made more than 30 billion single calculations within two months.
via Bing News